Viral protection: a four step plan for eliminating HPV-caused cancers in Europe. by Baker, Peter et al.
Viral Protection: Achieving the Possible
A Four Step Plan for 
Eliminating HPV Cancers
in Europe
The HPV Action Network is one of the European 
Cancer Organisation’s Focused Topic Networks, 
established as part of our Strategy for 2020-2023.  
The HPV Action Network was launched in December 
2019, following the resolution passed at the 2019 
European Cancer Summit in September: ‘By 2030, 
effective strategies to eliminate cancers caused 
by HPV as a public health problem should be 
implemented in all European countries.’ 
 
The HPV Action Network urges Europe to make 
HPV cancer elimination a formal European shared goal. Europe’s Beating Cancer 
Plan and other Regional/EU/National initiatives present significant opportunities for 
progress to be made. 
 
Co-chaired by Professor Daniel Kelly, European Oncology Nursing Society (EONS), 
and Professor Rui Medeiros, Association of European Cancer Leagues (ECL), the HPV 
Action Network convenes Member Societies and Patient Advocacy Groups of the 
European Cancer Organisation, as well as our Community 365 and other interested 
stakeholders. The up-to-date list of the Network participants is available on the 
Network website and acknowledged on the inside back cover of this report.  
 
More information is available on our website:  
www.europeancancer.org/topic-networks/1:hpv-action 
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FOREWORD 
 
Now is the time for ambition. Now is 
the time for inspiration. Now is the time 
for decisive action to create an HPV-
cancer-free future for men and women 
across Europe.  
 
This report has been written with the 
input and endorsement of a wide range 
of organisations and individual experts 
with an interest in cancer and HPV. It is a 
multi-disciplinary and inter-professional 
initiative that constitutes a public appeal 
to decision-makers across Europe to 
seize the moment.  
 
The new World Health Organization 
(WHO) strategy for the global 
elimination of cervical cancer as a 
public health problem, together with 
the forthcoming Europe’s Beating 
Cancer Plan, the EU Cancer Mission 
and the EU4Health Programme, create 
a unique opportunity for Europe to 
be an international regional leader 
in replicating what has already been 
achieved for another once-endemic 
virus, smallpox – the elimination of all 
the cancers and diseases caused by 
HPV. 
 
OUR CENTRAL RECOMMENDATION 
 
The European Union and the wider 
WHO European region should commit 
to the core goal of matching and 
exceeding the WHO Global Strategy 
for Cervical Cancer Elimination and 
implement policies and strategies for 
the elimination of all the cancers and 
diseases caused by HPV. 
This goal is achievable through 
evidence-based steps in four key areas: 












This report sets out how this goal can 
be realised through realistic investment 
and by building on good practice 
already in place in many but not all 
European countries. 
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Executive Summary
• HPV (human papillomavirus) is a very common 
sexually transmitted infection that causes almost 
5% of all cancers in women and men worldwide. 
These include cervical, anal, penile, vaginal, vulval 
and oropharyngeal cancers.
• HPV also causes genital warts and recurrent 
respiratory papillomatosis (RRP).
• Diseases caused by HPV can be prevented 
through vaccination. Ideally, this should be done 
in adolescence, before exposure to the virus.
• HPV vaccination is most effective if provided to 
both sexes. However, most countries in Europe 
do not currently vaccinate boys. HPV vaccination 
uptake also remains low in some countries.
• Cervical cancer screening is available in most 
European countries but only a minority of 
programmes can be described as adequate. 
Moreover, most countries do not yet offer HPV 
testing, now recognised to be the most effective 
screening method. The uptake of cervical cancer 
screening also varies widely within and between 
countries. Self-sampling HPV testing could play an 
important role in increasing uptake.
• Treatment outcomes vary widely across European 
countries, with five-year survival rates for cervical 
cancer ranging from 54-80%. 
• There are very concerning gaps in public and 
professional awareness of HPV issues and a 
significant risk that vaccination programmes in 
particular will be affected by safety fears fuelled 
by ‘fake news’.
• The COVID-19 pandemic has had a serious 
adverse impact on vaccination and screening 
programmes. This problem must be addressed as 
soon as possible.
The European Cancer Organisation is calling 
for urgent evidence-based policy and practical 
action by the EU and all governments throughout 
the WHO European region to eliminate cancers 
and diseases caused by HPV. The goals must 
include:
1. Universal (or ‘gender-neutral’) HPV vaccination for 
adolescents and optimal levels of uptake.
2. National organised population-based cervical 
cancer screening programmes using HPV testing 
systems and with higher levels of uptake.
3. Cancer treatments consistently and equitably 
offered in line with best practice guidelines and 
care and support that maximises patients’ quality 
of life. 
4. Action to improve public and professional 
awareness and education about HPV in order to 
improve vaccination and screening uptake.
HPV vaccination 
is most effective if 
provided to both 
sexes.
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Introduction
At the European Cancer Organisation’s annual 
European Cancer Summit held in Brussels in 
September 2019, a consensus resolution was passed 
by over 300 cancer stakeholders. It stated that: 
‘By 2030, effective strategies to eliminate cancers 
caused by HPV as a public health problem should 
be implemented in all European countries.’
In December 2019, at a meeting in the European 
Parliament in Brussels, the European Cancer 
Organisation launched the HPV Action Network. This 
involves the widest possible range of professional, 
patient and civil society organisations at both the 
Europe-wide and national levels. It aims to influence 
the policy, practice and research agendas 
by engaging with clinicians and academics, 
politicians, government officials and those working 
for European or international agencies, professional 
associations, civil society organisations and the 
general public. The HPV Action Network’s area of 
activity extends beyond the European Union and 
covers the 53 countries in the wider WHO European 
region.
The European Commission’s new Beating Cancer 
Plan, currently under development and due 
to be published in late-2020, provides a major 
new opportunity for the development of a 
comprehensive set of recommendations to, and 
support for, Member States that aim to reduce 
the cancer burden caused by HPV and address 
inequalities between EU countries. Encouragingly, 
the European Commission’s Roadmap for the 
Beating Cancer Plan specifically mentions HPV as a 
potential area for action.1
The new EU Cancer Mission, as part of the 
forthcoming Horizon Europe Framework Programme 
for Research and Innovation, creates an opportunity 
for complementary action. Additionally, the new 
EU4Health Programme could support HPV cancer 
and disease elimination by developing tools such as 
a European Cancer Dashboard to monitor progress 
towards vaccination, screening and treatment 
goals. 
There is already significant support for the 
introduction of universal vaccination across 
Europe. The European Parliament, in its resolution 
on vaccine hesitancy adopted in 2018, welcomed 
‘the encouraging progress made in the fight 
against HPV diseases and cancers thanks to 
vaccination programmes against the HPV virus’ 
and called on Member States ‘to further develop 
these programmes and explore ways to increase 
coverage rates and prevent other forms of cancer, 
for example by including boys in vaccination 
programmes.’2
WHO Europe’s men’s health strategy, adopted in 
2018, contains a recommendation that its Member 
States should consider a wide range of measures to 
improve the health and well-being of men and boys 
including ‘promoting the role of adolescent boys 
and men in policies, programmes and services 
related to […] sexually transmitted infections.’3 Almost 
half of all the countries in the WHO European Region 
now provide HPV vaccination to both sexes or plan 
to do so.
The WHO has a global strategy to accelerate 
cervical cancer elimination, with clear goals and 
targets for the 2020–2030 period. The strategy calls 
for global targets of 90% of girls to be vaccinated 
by the age of 15, 70% of women to be screened with 
a high-precision test at 35 and 45 years of age, 
and 90% of women with cervical disease to receive 
treatment and care.4 The WHO strategy provides 
a target for Europe and also the basis for a more 
ambitious programme to tackle all the cancers 
caused by HPV.
Europe can act as a beacon to other global regions 
to show what can be achieved when countries work 
together to achieve a major public health goal. 
Action across the European region to eliminate 
the cancers and diseases caused by HPV has the 
potential to save hundreds of thousands of lives 
and improve the quality of life of many more. 
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The Impact of HPV
HPV (human papillomavirus) is a very common 
sexually transmitted infection that causes 4.5% 
of all cancers in women and men worldwide.5 In 
the European continent, about 2.5% of cancers 
are attributable to HPV. The virus causes more 
than cervical cancer; it is also responsible for a 
high proportion of anal, penile, vaginal, vulval and 
oropharyngeal cancers. The virus is also responsible 
for genital warts and recurrent respiratory 
papillomatosis (RRP).
Almost all (85-90%) sexually active women and 
men will acquire HPV at some point in their lives.6 
There are around 200 different types of HPV. 12 of 
these HPV types are associated with a high risk of 
cancer7, the most significant being types 16 and 
18. HPV types 6 and 11 are not carcinogenic but
can cause warts on or around the genital area. 
They are also implicated in recurrent respiratory 
papillomatosis (RRP), a relatively rare but very 
disabling condition that adversely affects breathing 
in children and adults of both sexes. 
In some European countries, the prevalence of 
high-risk HPV infection exceeds 15% in women.8 
One study of oncogenic HPV types in men found a 
prevalence rate of 12%.9 In men who have sex with 
men specifically, the prevalence rate of HPV types 
16 or 18 could be as high as 20%.10 High-risk oral HPV 
infection specifically has been found to be much 
more prevalent in men than women.11 
Most people exposed to HPV suffer no ill-effects. 
But some, particularly those who are repeatedly 
exposed to high-risk HPV types or who are already 
immunocompromised (e.g. because they are HIV+), 
may go on to be diagnosed with a cancer caused 
by HPV. 
 HPV is implicated in virtually all cases of cervical 
cancer and around 90% of anal cancers. Estimates 
vary concerning the role of HPV in other cancers 
but one global analysis suggested that it causes 
12%–63% of oropharyngeal cancers, 36%–40% of 
penile cancers, 40%–64% of vaginal cancers, and 
40%–51% of vulvar cancers.12 There is some greater 
uncertainty about the proportion of oropharyngeal 
cancers caused by HPV. A 2018 global study 
concluded that HPV was responsible for 30% of 
oropharyngeal cancers13 while the CDC (Centers for 
Disease Control and Prevention) in the USA suggests 
70%.14
For the other cancers, the CDC estimates that 91% of 
anal cancers are caused by HPV, 63% of penile, 75% 
of vaginal and 69% of vulval. For all the cancers that 
can be caused by HPV combined, including cervical 
cancer, the CDC considers that HPV is implicated in 
79% of cases. The CDC estimate does not include a 
small proportion of other head and neck cancers, 
affecting the sino-nasal tract, the oral cavity and 
the larynx, that can also be caused by HPV.
If 2.5% of cancers in Europe are HPV-related, this 
suggests that about 67,500 cancer cases out of a 
total of 2.7 million15 across the 27 EU states will be 
caused by HPV in 2020. More specific studies have 
estimated that HPV is responsible for about 53,000 
new cases of cancer annually across 31 European 
countries,16 and 87,000 across the wider WHO 
European region.17 About 20% of cases occur in men, 
although one study suggests the proportion could 
be closer to 30%.18 In recent years, there has been a 
marked increase in the incidence of oropharyngeal 
cancers, mainly caused by HPV type 16, particularly 
in men.19 In the USA, HPV-positive oropharyngeal 
cancer has overtaken cervical cancer as the most 
common HPV-associated cancer type.20
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Almost all (85-90%) of sexually active 
women and men will acquire HPV 
at some point in their lives. There are 
around 200 different types of HPV.  
12 of these HPV types are associated 
with a high risk of cancer
If 2.5% of cancers in Europe are HPV-
related, this suggests that about 67,500 
cancer cases out of a total of 2.7 million 
across the 27 EU states will be caused by 
HPV in 2020.
ACTION AREA 1: 
HPV Prevention Via Gender 
Neutral Vaccination 
Programmes
HPV-related cancers and genital warts can be 
prevented by HPV vaccination. This is most effective 
when administered in adolescence, before exposure 
to the virus through sexual activity. There is, however, 
value in vaccinating older teenagers and young 
adults, at least up to the age of 26 because it can 
protect against a new infection or re-infection and 
block transmission to a new partner.25 In the USA, 
HPV vaccination is now recommended for all men 
and women up to the age of 26. There is also some 
evidence supporting the vaccination of all women 
up the age of 30 (or older) at the same time as a 
cervical screen;26 this approach is currently being 
considered in Sweden.27
When HPV vaccination programmes were 
first introduced, three separate doses were 
recommended to ensure optimal immunity. It 
has since been recognised that two doses are 
sufficient and research is currently underway in 
Costa Rica and elsewhere to determine the efficacy 
of a single dose regime. This follows evidence 
that women in current programmes who did not 
receive the recommended number of vaccinations 
nevertheless appear to be well-protected.28 If a 
single dose proves to be effective, this would have 
a major impact worldwide, making it easier and 
cheaper to deliver vaccination programmes. The 
public health benefits in low-income countries 
would be particularly significant.
The impact of HPV vaccination on cancer incidence 
is clear and significant. A large-scale study in 
Scotland found that, compared with unvaccinated 
women born in 1988, vaccinated women born in 
1995 and 1996 had an almost 90% reduction in 
the highest-risk cervical pre-cancers (Cervical 
Intraepithelial Neoplasia [CIN], i.e. cervical pre-
cancer, grade 3 or worse), an almost equivalent 
reduction in CIN grade 2 or worse and a near-80% 
reduction in CIN grade 1.29
100% vaccine effectiveness was demonstrated 
over 12 years in four Nordic countries: no cases of 
high-grade cervical dysplasia linked to HPV types 
16 or 18 were found in a large sample of vaccinated 
women.30 The incidence of genital warts has also 
been significantly reduced by HPV vaccination.31 The 
US Food and Drug Administration (FDA) has recently 
approved vaccination as a means of preventing 
head and neck cancers caused by HPV.32
The almost unique potential of HPV vaccination 
for improving public health is clear. Compared 
to many other cancer prevention interventions – 
such as tobacco control, reducing risky alcohol 
consumption, increasing physical activity or 
tackling obesity – it is easy-to-deliver, has an 
immediate impact and is highly effective. 
No data is available on the total number of cancer 
deaths in Europe caused specifically by HPV. 
However, data is available for cervical cancer 
specifically. In Europe, in 2018, there were almost 
26,000 deaths attributable to cervical cancer, of 
which about 16,000 were in Central-Eastern Europe, 
2,100 in Northern Europe, 3,500 in Southern Europe, 
and 4,250 in Western Europe.21 The cervical cancer 
mortality rate was significantly higher, almost 
threefold, in Central-Eastern Europe.
Every case of genital warts is caused by HPV. There 
are between 379,000 and 510,000 new cases of 
genital warts in women and between 377,000 
and 428,000 new cases in men annually across 31 
European countries. There is no Europe-wide data 
on RRP but the prevalence in the United Kingdom 
has been estimated at about 1.5 per 100,000.22 Both 
genital warts and RRP can have a significant impact 
on quality of life and treatments are costly.23,24
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100% vaccine effectiveness was 
demonstrated over 12 years in four 
Nordic countries: no cases of high-
grade cervical dysplasia linked to HPV 
types 16 or 18 were found in a large 
sample of vaccinated women.
The Case for Universal HPV 
Vaccination 
The vaccination of females alone will not provide 
effective protection for men against HPV infection. 
Unvaccinated females – such as those too old to 
have been offered routine vaccination or women 
who, although eligible, did not receive it – remain 
at risk of infection and can pass the virus on. In 
Europe as a whole, only about 4% of all women are 
estimated to have been vaccinated; in Northern 
Europe, the best-performing region, the figure rises 
to only 8%.33 Although these statistics are expected 
to improve over time as more women receive the 
vaccine, they do indicate the extent of the HPV 
infection ‘reservoir’. 
Heterosexual men living in countries with relatively 
high female HPV vaccination rates remain at risk 
of infection from unvaccinated women locally, 
as well as from women from countries with low-
uptake, or no, vaccination programmes. Men who 
have sex with men are at particular risk as they 
are completely unprotected by female-only HPV 
vaccination programmes, even in countries with 
very high levels of uptake by girls. It should be 
noted that HPV can also be transmitted between 
unvaccinated female sex partners.34
The case for vaccinating boys against HPV is 
reinforced by the fact that men have a poorer 
immune response to HPV infection than women. 
Men are less likely to seroconvert following infection, 
leaving them more vulnerable to re-infection.35 
HPV infection rates appear to stay constant in men, 
independent of age,36 whereas HPV prevalence in 
women is highest during 18–24 years of age and 
then decreases until middle age.
Vaccinating both sexes against HPV (known as 
‘universal’ or ‘gender-neutral’ vaccination) provides 
much greater levels of protection for everyone. 
Its efficacy lies in preventing the transmission of 
HPV between the sexes and in same-sex couples, 
reducing the circulation of the virus overall and 
creating what is termed ‘herd protection’. Universal 
HPV vaccination is an especially important public 
health strategy in countries where vaccination 
uptake in girls is relatively low. 
Universal HPV vaccination is consistent with the 
fundamental human right to the highest attainable 
standard of health. Excluding men is unfair, and in 
some jurisdictions possibly unlawful on grounds 
of sex discrimination, as it makes a potentially 
life-saving intervention unavailable solely on 
the grounds of sex. Universal vaccination would 
also lead to greater equity between the sexes, 
between countries, and between income groups 
(in the absence of national programmes, wealthier 
families are choosing to purchase vaccines for their 
sons or daughters). 
Universal HPV vaccination programmes also 
remove from females the sole responsibility for 
preventing HPV infection and help to overcome 
stigma about female vaccination based on 
unfounded concerns that it might encourage 
‘promiscuity’. Universal programmes are also more 
resilient to unexpected falls in uptake, for example 
as a result of unfounded scares spread by ‘fake 
news’.37
Vaccinating both sexes against HPV provides an 
effective and faster approach to preventing or 
reducing the incidence of cancers and other HPV-
related diseases. A universal approach could make 
the elimination of HPV-caused diseases possible 
even with moderate levels of vaccination uptake 
(50-75%).38
The European Centre for Disease Prevention and 
Control (ECDC) has suggested that if the objective 
of HPV vaccination is to prevent all HPV-caused 
disease, rather than cervical cancer alone, then 
universal vaccination may be a cost-effective 
option.39 In 2018, the highly-influential Joint 
Committee on Vaccination and Immunisation 
(JCVI), the UK government’s vaccination advisory 
committee, concluded that vaccinating both boys 
and girls is cost-effective, even when over 80% of 
girls are vaccinated, if the impact of HPV-related 
diseases in the long-term is taken into account.40 It 
should be noted, however, that cost-effectiveness 
modelling is contingent on highly variable 
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A total of 26 countries are 
currently, or will be, including 
boys in their national HPV 
vaccination programmes; this 
represents almost half (48%) of 
all countries in the region. 
assumptions (e.g. vaccine price, the proportion of 
cancer cases attributable to HPV and the costs 
of treatments) and, in any event, should not be 
the sole factor in decision-making about access 
to vaccines. Issues of equity, ethics and patient 
experience must also be taken into account.41
25 EU countries now provide national HPV 
vaccination programmes for girls. (The exceptions 
are Romania and Poland, although Poland plans 
to introduce a girls’ programme in 2021.) 40 out of 
54 countries across the WHO European region as a 
wholea have national HPV vaccination programmes 
for girls.42
Boys are currently included in national HPV 
vaccination programmes in ten out of 27 EU 
countries and in eight other countries in the rest of 
the WHO European region. Finland, France, Hungary, 
the Netherlands, Poland, Portugal, Slovenia and 
Sweden have made a commitment to introduce 
HPV vaccination for boys. A total of 26 countries 
are therefore currently, or will be, including boys in 
their national HPV vaccination programmes; this 
represents almost half (48%) of all countries in the 
region. 
Figure 1. Countries in WHO European region with national HPV vaccination programmesb
GIRLS ONLY
(*where planned to 
include girls)
UNIVERSAL
(*where planned to 
include boys)
Countries in WHO 
European region 







a  Includes Liechtenstein, which is not a WHO Europe member.
b  Information about vaccination policies in specific countries may not be complete as up-to-date information for 
every state in the WHO European Region is not readily available. The same caveat applies to the section below on 
cancer screening.
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40 out of 54 countries 
across the WHO European 





Generally, countries in Northern, Western and some 
parts of Southern Europe are more likely to have 
an HPV vaccination programme, as compared to 
Eastern European countries. With some exceptions, 
the HPV vaccination programmes that include boys 
are located in Northern and Western Europe.
Universal HPV vaccination programmes are also 
becoming more common outside Europe. It is 
thought that 42 countries worldwide are currently 
vaccinating both boys and girls against HPV, 
including Argentina, Australia, Barbados, Bermuda, 
Brazil, Canada, Guyana, New Zealand, Trinidad and 
Tobago and the United States. 
A few countries, including France and the UK, have 
introduced HPV vaccination programmes targeted 
specifically at men who have sex with men and 
other high-risk groups, such as sex workers. Such 
programmes have relatively low levels of uptake 
and their users are generally of an age where they 
are highly likely to have already been exposed 
to HPV infection.43,44 While they cannot be seen 
as a substitute for universal vaccination, these 
programmes can play an important role if properly 
resourced, especially since it will take many years 
before HPV vaccination programmes currently 
delivered to adolescents protect adults at higher 
risk. Migrants are another high-risk group which 
could benefit from targeted vaccination (as well as 
cervical cancer screening) programmes.45
There is currently a short-term global shortage 
of HPV vaccine and the WHO has recommended 
that countries ‘should temporarily pause 
implementation of boy, older age group (>15 years) 
and multi-age cohort (MAC) HPV vaccination 
strategies until vaccine supply allows equitable 
access to HPV vaccine by all countries’.46 This is 
intended to support cervical cancer prevention 
programmes in mainly low-income countries. Fewer 
than one in three girls lives in a country in which HPV 
vaccine is in the national immunization schedule, 
and those at greatest risk for cervical cancer are 
least likely to have access, as only 13 low-income 
countries have so far introduced the vaccine. 
The HPV vaccine shortage is expected to be 
resolved by 2023 (perhaps earlier if new vaccines 
manufactured in China become available), 
meaning that European countries have an 
opportunity to develop their plans over the next 2-3 
years and have them ready for implementation 
in 2023 or soon after. In the meantime, European 
countries, and the EU itself, could offer support to 
low-income countries developing HPV prevention 
programmes.
Vaccination Uptake
HPV vaccination uptake in females varies 
significantly across EU countries – few meet the 
widely-accepted target of at least 80% coverage.47 
In some countries, such as Bulgaria, France and 
Greece, vaccination rates are particularly low.
In Western and Southern Europe, about one-third of 
females in the targeted populations is estimated to 
have completed the full course of HPV vaccination. 
In Eastern Europe, the proportion is only one-fifth. 
However, in Northern Europe, the best-performing 
region, about two-thirds of eligible females have 
been vaccinated.
HPV vaccination rates can also vary widely within 
countries themselves. The UK, for example, has 
a high overall vaccination rate (just over 80%) 
but, at the local level, uptake varies between 50% 
and 95%.48 There is evidence of lower rates of 
uptake among ethnic minority communities and 
disadvantaged socio-economic groups in both 
Europe and the USA.49
Low vaccination uptake has a range of causes, 
including cost, restricted access to health services, 
concerns about vaccine safety and lack of service 
co-ordination, which need to be better understood 
for each country. But action is needed to improve 
HPV vaccine delivery systems (school-based 
systems generally have higher levels of uptake 
and are usually considered to represent best 
practice but other models, such as Portugal’s 
use of community health clinics, can also be very 
effective) and to reassure the public, using robust 
scientific evidence about vaccine safety. Guidance 
about best practice would be very helpful, 
especially for those countries wishing to launch, 
develop or expand their vaccination programmes.
The COVID-19 pandemic has significantly disrupted 
HPV vaccination programmes across Europe and 
will undoubtedly cause a dip in uptake, at least 
in the short-term. The European Federation for 
Colposcopy (EFC) and the European Society for 
Gynaecological Oncology (ESGO) suggest that 
HPV vaccination can continue in countries with no 
cases or sporadic cases of COVID-19 but should be 
delayed in countries with clusters of cases and/or 
community transmission and where the mobility 
of vaccine recipients and healthcare staff must be 
restricted to restrict transmission of the SARS-CoV-2 
virus.50 
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The JCVI has advised that, for the UK, the priority is 
for all eligible children to receive at least the first 
dose of the HPV vaccine.51 The committee considers 
that the interval between the first and second dose 
can be extended by a number of years without 
compromising protection or the boosting effect of 
the second dose. 
EFC and ESGO consider that careful planning is 
needed to handle the backlogs accumulated due 
to COVID-19 to minimise drops in mid- and long-
term HPV vaccination coverage. Measures should 
be taken to complete vaccination schedules for 
those who have already started HPV vaccination, 
assuring an interval less than 12-15 months from 
the first dose. Some local vaccination teams 
have developed innovative ‘drive through’ HPV 
vaccination schemes to reach children who would 
normally have been vaccinated at school.52 There 
may also be a potential role during the pandemic 
for community pharmacists.53
CASE-STUDY
Drive-Through HPV Vaccination Clinics
COVID-19 meant that the school nursing 
service in the Isle of Wight in Southern England 
was unable to complete scheduled range of 
childhood immunisations in schools prior to their 
enforced closure. Recognising the vital need 
to vaccinate as many children as possible, the 
service worked with partner organisations to 
reconfigure the delivery system. Drive-Through 
immunisation clinics were quickly developed and 
launched.
‘Pods’ with power and hot water were 
established in local council car parks. Parents 
were contacted, the process was explained 
and they were given an appointment time. The 
programme at first focused on the routine child 
health immunisation programme but it worked 
so well that the model was extended to HPV 
vaccinations. 
This approach has been extremely well received 
by families. Comments received included: ‘Thank 
you so much for today; it was an absolute breeze, 
no fuss, clear instruction and quick and efficient 
service.’ ‘’X... was super anxious beforehand but 
the school nurses were all so kind and welcoming 
and they put him completely at ease. Fabulous 
team.’ In the context of the Coronavirus, being 
able to offer the service in the open air gave 
parents more confidence than a traditional clinic 
setting.
It is too soon for data analysis but the school 
nursing service is confident that immunisation 
uptake and coverage is much better than it 
would have been due to restrictions of the 
Coronavirus. This approach has now gone ‘viral’ 
with numerous UK-wide children and young 
people immunisation providers adopting this 
model of practice as well as other health services 
such as asthma check-ups for children. 
- Sharon White, CEO, School and Public Health 
Nurses Association (UK)
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• As part of an overall EU ambition for eliminating HPV cancers and diseases, 
Europe’s Beating Cancer Plan should encourage all EU member states to 
implement gender-neutral vaccination programmes. Progress towards this goal 
should be monitored via a European Cancer Dashboard.
• By 2025, all European country cancer plans should include actions towards 
achieving population-based and gender-neutral HPV vaccination, if not already in 
place.
• By 2030, gender-neutral vaccination programmes against HPV infection should be 
in place in all European countries.
• The target vaccination rate by 2030 in all European countries should be at least 
90% of adolescents of both genders completing the full course with particular 
attention paid to ensuring equitable access for all demographic groups. 
• Supplementary to gender-neutral vaccination programmes, consideration should 
be given to the needs of high-risk groups, including men who have sex with men, 
migrants and sex workers, that may otherwise fall outside of the age parameters of 
the universal vaccination programme. 
• Consideration should be given to extending routine vaccination programmes to 
older age groups on a gender-neutral basis.
• Best practice guidance should be developed and published by the WHO and/or EU 
on how HPV vaccination programmes can be delivered to ensure optimal uptake.
• In support of vaccination goals, global cooperation should be fostered, through 
WHO or other organisations, to resolve vaccine supply issues to ensure no country’s 
HPV vaccination programmes are impacted because of shortages. The EU should 
work with vaccine manufacturers to ensure that the supply of vaccines is sufficient 
in future to meet the growth in demand. Current global supply issues need not 
impact adversely on the timescales proposed in these recommendations.
• Action must be taken to ensure minimum disruption to HPV vaccination 
programmes by COVID-19.
Recommendations on Vaccination
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ACTION AREA 2: 
Early Detection by HPV 
Testing
Late diagnosis of cancer increases the risk of 
serious disease and death. Cervical cancer 
screening can reduce cervical cancer mortality by 
up to about 90%, according to a study of its impact 
in Europe.54 Screening programmes will remain an 
essential element of the management of cervical 
cancer for the foreseeable future. This is because 
vaccination only began in Europe in 2008 and 
there are no countries that have achieved 100% 
vaccination uptake. Moreover, vaccination does 
not protect from all the oncogenic HPV types and 
some cases of cervical cancer are not caused by 
HPV. Many millions of women therefore remain at 
risk of HPV infection and cervical cancer. As the 
vaccinated cohort expands, however, screening will 
become a more straightforward process for women 
and clinicians. 
Currently there are no screening programmes 
available for any of the other HPV-caused 
cancers, including those affecting men. Currently-
available screening tests for oropharyngeal 
cancer are insufficiently accurate and the benefits 
and potential harms (such as overdiagnosis or 
unnecessary treatment of patients with false-
positive results) are unknown.55 Screening for anal 
pre-cancers is technically possible and has been 
suggested for high-risk groups, such as men who 
have sex with men, people with HIV/AIDS, and 
women with a history of HPV-caused cervical, 
vaginal or vulval cancers. However, the evidence of 
benefit has not yet been clearly established.56
More research is needed into potential screening 
programmes for the non-cervical HPV-caused 
cancers; in the meantime, the best way of achieving 
early diagnosis is through public education about 
the symptoms and training the medical workforce, 
including dentists, to detect the early signs of all 
cancers. It has been suggested that dentists and 
dental hygienists may have a potentially important 
role in the opportunistic detection of oral lesions 57,58 
but robust evidence for this approach is currently 
lacking, particularly in the case of oropharyngeal 
cancer.
A recent analysis of cervical cancer screening 
across 46 European countries found that, with 
the exception of one country (Azerbaijan), all 
had a screening programme of some sort.59 17 
had population-based organised programmes 
described as ‘mature’ and 11 had ‘nascent’ 
organised population-based programmes. 
Organised population-based screening refers to 
an approach in which invitations to screening are 
systematically issued by public authorities to a 
defined target population, within the framework of a 
documented public policy specifying key modalities 
for screening examinations. This approach is 
recommended in the European Guidelines for 
Quality Assurance in Cervical Cancer Screening.60
Another 16 countries had opportunistic 
programmes, meaning that their success depends 
on the initiative of individual women and their 
doctors. This approach to screening often results 
in high coverage only in certain parts of the 
population, while other groups, usually with a lower 
socioeconomic status, have more limited uptake. 
Opportunistic programmes result in not only uneven 
coverage but also less consistent quality assurance, 
limited impact, and reduced cost-effectiveness.61 
Also, while cervical cancer screening and cancer 
treatment is free of charge in most Eastern 
European and central Asian countries in the WHO 
European region, few cover the cost of following 
up a positive screening test or the treatment of 
precancerous lesions.62 The value of free cervical 
cancer screening at no cost is limited unless the 
treatment of precancerous disease is also provided 
free of charge.
Uptake of screening is highly variable between and 
within countries. Rates vary from over 70% in some 
EU member states to around 30% in others.64 The 
highest recorded rate is in Sweden (83% in 2017) 
and the lowest in Romania (1%). In countries with 
historically high screening rates, uptake has been 
falling in recent years. Overall, in 2014, about 14% of 
EU women aged 20-60 had never had a Pap smear 
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test. In every country, women with lower educational 
attainment are least likely to have been screened. 
HPV testing is the most effective, and accurate, 
method of cervical cancer screening. It is supported 
by the European Guidelines for Quality Assurance 
in Cervical Cancer Screening65 and is now being 
adopted by an increasing number of countries in 
place of cytology-based screening. However, it is 
not yet universal. Finland, France, Germany, Italy, 
The Netherlands, Spain and Sweden, as well as 
Norway, Turkey and the United Kingdom outside of 
the EU, have either started to implement HPV testing 
on a regional or national level or plan to do so. It 
has also been piloted in several other countries, 
including Poland and Portugal.66 
Figure 2. Countries in the WHO European region with cervical cancer screening programmes63
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Uptake of screening is highly variable 
between and within countries. Rates 
vary from over 70% in some EU member 
states to around 30% in others. 
As part of the process of introducing HPV testing, 
women need to be fully informed about the nature 
of the test (for example, they need to know that 
being HPV positive is not on its own evidence of 
a pre-cancerous lesion) and to understand the 
nature of HPV infection in order to avoid potential 
relationship difficulties and stigma. In the absence 
of this understanding, some may believe they 
have acquired the virus from an unfaithful partner 
or their partner may assume that she has become 
HPV+ as the result of sexual activity outside of 
their relationship. There is also a need for clinical 
consensus about how best to follow-up positive 
tests.
HPV testing does not have to be clinic-based. HPV 
self-sampling is now an option. Women use a kit, 
either provided at a clinic, sent to their homes or 
delivered there by a health worker. Greater use 
of this tool could undoubtedly help to improve 
access to screening programmes and improve 
uptake.67 It may be particularly suitable for women 
who are unable to access standard screening 
facilities, perhaps because they live in countries 
with less provision or in remote areas or have a 
disability, or where there are cultural barriers or 
previous traumatic experiences. It is essential, 
however, that self-sampling programmes address 
the potential risks of lower rates of follow-up by 
patients or increased patient anxiety following a 
positive result.68
Self-sampling has already been incorporated into 
the cervical cancer screening in the Netherlands 
and in the Capital Region of Denmark69 and 
should be considered for wider roll-out across 
Europe. Self-sampling could also help mitigate the 
disruption caused to cervical cancer screening 
programmes by COVID-19 although it is essential 
that ‘mainstream’ screening resumes, where it is 
safe to do so, as soon as possible following the 
guidance developed by EFC and ESGO.70
CASE-STUDY
HPV Testing in Turkey
A cytology-based cervical cancer screening 
programme was introduced in Turkey in 2004 but 
only reached 3% of the target population by 2012. 
Key barriers included a lack of coloscopists and 
cytopathologists and poor quality assurance for 
the testing process.
HPV testing was introduced in 2014 in an attempt 
to increase screening uptake, to provide a more 
accurate test, and to eliminate the human 
resource bottleneck. Women aged 30-60 were 
now invited for screening every five years, a 
well-defined protocol for screening intervals and 
referrals was introduced, and a single nationwide 
centralised diagnostic laboratory was estab-
lished. The testing service was delivered by family 
physicians and nurses. 
Two samples are taken from each woman which 
enables cytology testing for those found to be 
HPV-positive without women having to return for 
a separate test to provide an additional sample. 
Because only HPV-positive tests have to proceed 
to cytology, larger numbers of women can be 
screened without an excessive burden being 
placed on the coloscopy and cytopathology 
workforce.
HPV testing enabled a ten-fold increase in 
screening coverage to be achieved by 2017, by 
that time reaching 35% of the target population. 
The uptake among 30-45 year olds specifically 
reached 64%. The success of the programme 
suggests that HPV testing could be a feasible 
option for other upper-middle-income and 
socially conservative states in the European 
region.
-Guletkin M, Karaca MZ, Kucukyildiz I, et al.71
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CASE-STUDY
HPV Self-Sampling
Women who are underscreened for cervical 
cancer are more likely to participate when 
offered HPV self-sampling kits, according to a 
trial in Belgium. 
The women, aged 25-64, were recruited 
from attendees at a GP practice in a Flemish 
municipality near Brussels who had not be 
screened for cervical cancer for at least three 
years. The GPs invited 50% of the women to 
use a a self-sampling kit. This could be used at 
home and then sent by post to a laboratory or 
returned to the GP practice. The other 50% of the 
women were asked to make an appointment 
for a Pap smear test at the practice or with a 
gynaecologist.
78% of the self-samplers completed the test 
compared to 51% of those offered a Pap test. 
Women in the self-sampling group were 1.5 
times more likely to participate in testing. The 
trial suggests that direct GP involvement leads 
to higher rates of self-sampling than other 
systems, such as sending kits to women by 
post. Other studies have also shown that the 
involvement of community health workers can 
lead to an increased uptake of self-sampling.
-Peeters E, Cornet K, Devroey et al.72 
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• By 2025, all European country cancer plans should include actions towards 
achieving a minimum 70% screening target, if not already achieved.
• By 2030, at least 70% of women in Europe should have been screened for cervical 
cancer with an appropriate high-precision HPV test within the last five years. This 
coverage should be reached, at minimum, at 35 and 45 years of age, as part of an 
organised population-based programme. HPV screening programmes should take 
into consideration innovations such as self-sampling in respect to their potential 
for achieving higher rates of screening, particularly during the COVID-19 pandemic.
• In support of screening goals, EU guidelines on integrated HPV vaccination and 
cervical cancer screening should be regularly updated. A third edition of evidence-
based guidelines should be developed by 2021/2022 to take account of recent 
developments in HPV testing technologies (which are now capable of identifying 
high-risk infections that are present and active with both high accuracy and high 
specificity73) and to maximise the benefits for women and health professionals.
• More research is needed into improving the early detection of non-cervical 
cancers caused by HPV. This effort should be supported under the aegis of the EU 
Cancer Mission and Horizon Europe research programme.
• Progress on improving and widening access to HPV testing should be monitored by 
a European Cancer Dashboard.
Recommendations on Screening
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There are wide variations in survival from the 
various cancers caused by HPV. A study of patient 
outcomes in the USA found that the 5-year age-
standardised relative survival rate was 66% for 
vulval and anal cancers, 64% for cervical cancers, 
53% for vaginal cancers, 51% for oropharyngeal 
cancers and 47% for penile cancers.74
There are also wide variations in survival from 
specific HPV-related cancers across Europe. Among 
women diagnosed with cervical cancer between 
2010 and 2014, age-standardised five-year survival 
ranged from 80% in Iceland and 73% in Norway 
and Cyprus to 56% in Latvia and 55% in Poland and 
Bulgaria. The average among EU countries was 
63%.75,76 Similar inequalities have been identified 
concerning other HPV-caused cancer types: age-
standardised five-year survival among individuals 
diagnosed between 2000 and 2007 ranged from 
47% to 81%  for HPV-caused anal cancer,77 from 
40% to 65% for vaginal and vulval cancer, from 30% 
to 60% for penile cancer and from 30% to 65% for 
oropharyngeal cancer,78 across European countries. 
Survival rates are significantly lower in many Central 
and Eastern European countries, in part reflecting 
variations in access to high-quality cancer 
treatment and care. 
There are now consensus guidelines for the clinical 
treatment of the cancers caused by HPV which, if 
followed by practitioners, would help to achieve 
improved and more equitable outcomes across 
Europe. ESGO, the European Society for Radiotherapy 
and Oncology (ESTRO) and the European Society 
of Pathology (ESP) have developed guidelines for 
the management of patients with cervical cancer 
across Europe.79
A consensus statement on colposcopy, developed 
by ESGO and EFC will soon be published. It will 
recommend that women detected at risk of cervical 
disease in a cervical cancer screening programme 
should be referred to a trained colposcopist and 
provided with written information prior to their 
colposcopy. Furthermore, local treatment of CIN 
(cervical pre-cancer) should be performed under 
colposcopic guidance and whenever possible as 
an out-patient procedure under local anaesthetic.
Guidelines for the diagnosis, treatment and 
follow-up of anal cancer have been drawn up by 
the European Society for Medical Oncology (ESMO), 
the European Society for Surgical Oncology (ESSO) 
and ESTRO.80 Clinical practice in the field of head 
and neck cancers caused by HPV should follow best 
practice guidelines such as those developed by the 
National Cancer Institute in the USA81 or by a multi-
disciplinary group in the UK.82 For penile cancer, 
clinical practice guidelines have been published by 
ESMO.83
There are, clearly, resource implications for the 
successful implementation of clinical guidelines 
in terms of timely patient access to appropriate 
secondary care facilities (such as multi-disciplinary 
specialist cancer treatment centres), the availability 
of medicines, clinical staff training and other factors 
including public awareness of symptoms. These will 
be easier to achieve in some countries than others. 
Medical audits on cancer cases in each country 
could help to identify gaps in prevention strategies 
and be a catalyst for action.
Attention must also be paid to quality of life 
issues for people undergoing treatment and in its 
aftermath. Cervical cancer survivors commonly 
experience bladder and bowel dysfunction, sexual 
problems, lymphedema (swelling in the limbs) and 
psychosocial issues.84 Survivors of oropharyngeal 
cancer frequently face particular problems with dry 
mouth, swallowing, chewing and concerns about 
speech and appearance.85 Anal cancer survivors 
also suffer serious long-term impacts on their 
quality of life, including bowel, urinary and sexual 
problems.86
ACTION AREA 3:
Getting Better on HPV 
Cancer Treatment
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Among women diagnosed with cervical 
cancer between 2010 and 2014, age-
standardised five-year survival ranged 
from 80% in Iceland and 73% in Norway 
and Cyprus to 56% in Latvia and 55% 
in Poland and Bulgaria. The average 
among EU countries was 63%.
ACTION AREA 4:
Raising Awareness and 
Education
The WHO has identified vaccine hesitancy as one 
of the top ten health threats in the world. Efforts to 
eliminate the diseases caused by HPV risk being 
undermined by a lack of public awareness about 
HPV, the diseases it can cause and the importance 
of vaccination. ‘Fake news’ about vaccination 
safety generally and HPV vaccination specifically 
is often relayed by mainstream media reports and 
amplified by social media. This has recently been 
associated with rapid falls in uptake in Denmark, 
Ireland and Japan. In Denmark specifically, the 
uptake of the first HPV vaccine dose was around 
90% for girls born in the period 1998 to 2000 but 
dropped to 54% for girls born in 2003.87
• By 2030, across all European countries, a minimum of 90% of women with Grade 3 
cervical pre-cancer should be treated within three months; and a minimum of 90% 
of all invasive cervical cancer cases should have been detected and managed.
• By 2025, all European country cancer plans should include actions to achieve these 
cervical cancer treatment goals, if not already achieved. They should also contain 
actions to implement best practice guidelines for non-cervical cancers caused by 
HPV.
• All country cancer plans should ensure that quality of life issues are fully 
addressed.
• A European Cancer Dashboard, operating as part of the monitoring and 
implementation element of Europe’s Beating Cancer Plan, should provide regular 
publicly available updates on the progress being made towards these goals.
Recommendations on Treatment
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Recent research suggests 
that only 73% of people in 
Northern Europe believe that 
vaccines, in a general sense, 
are safe. In Western Europe, 
this figure is even lower, at 
59%; and in Eastern Europe 
this stands at 40%.
Recent research suggests that only 73% of people in 
Northern Europe believe that vaccines, in a general 
sense, are safe. In Western Europe, this figure is 
even lower, at 59%; and in Eastern Europe this 
stands at 40%.88 Across Europe, the main causes of 
HPV ‘vaccine hesitancy’ specifically are related to: 
insufficient and inadequate information about HPV 
vaccination; misinformation about the potential 
side effects of the vaccine; issues around trust in 
health authorities, doctors and in new vaccines; 
and a perception of low vaccine effectiveness.89 
There are differences between countries: in Italy, 
for example, there are greater concerns about the 
vaccine impacting negatively on sexual activity in 
younger women.
Many people currently lack basic knowledge about 
HPV and the associated risks. One study of men 
and women in the United Kingdom, where HPV 
vaccination for girls began in 2008 and systematic 
cervical cancer screening in 1988, found that 
just over one third (37%) had even heard of HPV.90 
Of these, 70% were aware that HPV could be 
transmitted during sex, and about 40% recognised 
that HPV could cause oropharyngeal cancer but 
only two thirds (64%) knew that a preventive vaccine 
existed. A study of some 17,000 Europeans across 
10 countries found that a quarter (24%) of people 
believed HPV to be ‘quite rare’ or ‘extremely rare’ 
and that over two thirds (70%) were not aware that 
HPV could cause cancer in males.91 There is also 
evidence that some women are deterred from 
screening because of a fear that it is a test for 
cancer rather than primarily a means of preventing 
cancer.
Online information provided about HPV, vaccination, 
cervical cancer and screening varies widely in 
terms of type and quality, according to a recent 
study conducted across 46 European countries.92 
In 37 countries, information is provided through 
a government website and in only 19 countries 
was the quality of the information judged to 
be ‘excellent’ or ‘good’ across four domains 
(information on HPV; information on cervical cancer 
and screening; information on ways to access 
vaccines; and online discoverability). In 10 countries, 
the quality of information was deemed ‘insufficient’ 
across the four domains, suggesting that there is 
considerable room for improvement.
It is not yet possible to be certain of the impact of 
COVID-19 on vaccine confidence and uptake. It is 
possible that the pandemic will serve to increase 
public understanding of viruses in general and the 
potential role of vaccines in disease prevention and 
generate greater faith in and respect for science 
and scientists. The pandemic has certainly been a 
stark reminder of the impact of a serious disease 
in the absence of a vaccine and any effective 
treatment. 
If a safe COVID-19 vaccine is successfully developed 
and delivered to millions of people worldwide, 
this could have a positive impact on vaccine 
confidence generally. But it is also apparent that 
COVID-19 has re-invigorated the anti-vaccination 
movement and sparked the proliferation of many 
patently absurd conspiracy theories.93 Vaccine 
scepticism may also be fuelled if participants in the 
COVID-19 vaccine trials suffer serious side-effects, 
if the vaccine (or vaccines) that are eventually 
deployed prove to be less effective than hoped, or 
if the governments that recommend them are not 
credible to their citizens because of their overall 
management of the pandemic.
There is a clear need to improve public knowledge 
about HPV-related health risks, to raise awareness 
of HPV in general, including the value of HPV 
screening and the safety of vaccination. The 
utilisation of a Precaution Adoption Process Model 
(PAPM), which describes the psychological stages 
individuals go through when making decisions 
about behaviour change, might be helpful.94 
In Ireland, a sharp decline in HPV vaccination 
uptake was successfully reversed in part by 
the dissemination of emotive stories of patient 
advocates; such stories can be more impactful 
than science-based communications. Celebrities 
may also have a role to play.
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A study of some 17,000 Europeans 
across 10 countries found that a 
quarter (24%) of people believed 
HPV to be ‘quite rare’ 
or ‘extremely rare’ and 
that over two thirds 
(70%) were not aware 
that HPV could cause 
cancer in males.
CASE STUDY
Tackling ‘Fake News’ on HPV Vaccination 
in Ireland
After an emotive political debate, Ireland 
introduced a free school-based HPV vaccination 
programme for 1st year secondary school girls 
in 2010. The programme enjoyed high levels of 
uptake until a targeted media campaign by a 
small group of anti-vaccination activists led 
to a national TV ‘shockumentary’ catalysing a 
freefall in vaccine confidence. This campaign 
was professionally executed at local and national 
levels to the extent that the viability of the 
programme came under threat.
Over the next few years, The HPV Vaccination 
Alliance, a coalition of NGOs, health agencies, 
professionals and those impacted by HPV cancer, 
developed and implemented a recovery strategy 
which has restored levels of vaccine uptake close 
to those needed to ensure maximum health 
benefit in the community.
First and foremost, this initiative focused on 
collaborative communication, collegiately uniting 
various stakeholders under the one banner of 
communicating the facts about the opportunity 
that HPV vaccination gives to eliminate a 
number of dreadful diseases. Clear concise, 
easy to understand public communication tools, 
including social media, were employed to target 
parents as well as those being vaccinated.
Educational initiatives were developed and 
provided to ensure that key and trusted public 
gatekeepers, such as nurses, doctors and 
pharmacists, had access to robust information 
and could reinforce positive public health 
messages about the vaccine. Time was also 
spent to ensure that politicians and media had 
easy and ready access to factual information.
Public cancer advocates lent their voice and 
considerable insight to illustrate why the 
vaccine is important to young people. Leading 
international agencies, including the WHO, 
engaged with and endorsed the campaign 
and this was further reinforced by strong and 
unambiguous political support at the very top 
level from the health and prime ministers. 
-Dr Robert O’Connor, Director of Research, Irish 
Cancer Society
Messages should be tailored to particular 
population sub-groups, differentiated by gender, 
sexuality, age, race and other identities. Action 
must be taken on a sustained basis but the 
annual HPV Awareness Day in March (run by the 
International Papilloma Virus Society), the European 
Immunisation Awareness Week in April and the 
European Cervical Cancer Prevention Week in 
January present particular opportunities, as do 
cervical cancer awareness weeks held at different 
times in individual countries. 
The education of health professionals, especially 
in primary care, is also of critical importance. 
Consistent and well-informed information and 
advice to patients from GPs, nurses, pharmacists 
and dentists can make a significant difference to 
the decisions individuals make about vaccination 
and screening. There is evidence of doubts about 
vaccine safety generally among healthcare workers 
in several countries95 and of a need for additional 
training in HPV vaccination and screening in 
particular.96 
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CASE STUDY
HPV e-Learning for Health Professionals
Distance learning has developed significantly 
in recent years. It has become an increasingly 
important part of the global mandate of the 
Education for All movement led by UNESCO and 
the COVID-19 pandemic has hugely reinforced 
its importance, not least for the training of health 
professionals.
The Cancer Epidemiology Research Programme 
at the Catalan Institute of Oncology (ICO) along 
with the ICO e-learning programme e-oncología, 
(www.e-oncologia.org), have been developing an 
extensive virtual training programme on HPV and 
associated diseases for over eight years.
The following courses are now available:
1. Cervical cancer prevention (launched 2011 
and now available in seven languages); 18,500 
students, to date.
2. Strategies in the primary and secondary 
prevention of cervical cancer (2017); 4,000 
students.
3. HPV Epidemiology and Prevention to Paediatrics 
and Primary Care (2018); 1,000 students.
4. HPV Vaccine Safety (2018); 6,000 students.
5. HPV-associated Head and Neck cancers: 
epidemiology, prevention and clinical 
management (2020); 500 students.
The digital content of all the courses has been 
developed using interactive elements and 
multimedia to facilitate learning. The modular 
structure of the courses allows for the addition of 
specific modules including the prevention and 
screening protocols for the country or region of 
interest.
The course is intended for a wide range of 
professionals, including health professionals 
involved in the prevention of cervical cancer, 
gynaecologists, paediatricians, oncologists, 
microbiologists, primary care physicians, nurses, 
midwives, public health professionals, health 
managers and planners, researchers and 
educators.
-Xavier Bosch, Director, e-oncologica and 
Assumpta Company Serrat, Academic Director, 
e-oncologica
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• By 2025 all European country cancer plans should include actions to increase 
public, patient and healthcare professional understanding and awareness about 
HPV. This awareness should include the range of related cancers and diseases, 
their symptoms and forms of prevention. Furthermore, this communication effort 
should elaborate to the public, patients and healthcare professionals the potential 
and need for HPV elimination, the strategies being pursued to achieve that goal, 
and the role of the public, patients and healthcare professionals. Awareness levels 
of the public, patients and healthcare professionals on HPV should be thereafter be 
monitored and reported on.
• These awareness raising actions should encompass the dental workforce, the 
schooling system, community pharmacists and nurses as well as physicians in 
primary and secondary care.
• By 2021, cancer societies, patient and healthcare professional associations, and 
other stakeholders, should publish a core list of consensus recommendations for 
European member states to implement in order to combat the impacts on HPV 
vaccination uptake posed by fake news. 
• By 2021, all major social media platforms operating in Europe should have 
developed and implemented effective strategies that build on already-
implemented measures to reduce significantly further the spread of fake news on 
vaccination.
• By the end of 2022, all national cancer plans in Europe should include actions 
to combat the deterrence effects of fake news upon HPV vaccination rates, as 
part of a broader campaign to reduce the negative impact of fake news on all 
vaccination programmes.
Recommendations on Public and Professional 
Awareness of HPV
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• By 2025, all European countries should have accountable population-based 
registries in place to track and report on HPV vaccination, HPV screening and HPV 
related (and other) cancer incidence, survival and mortality data. 
• ECDC should be given the authority to oversee the implementation of an EU goal to 
eliminate cancers caused by HPV.
• By 2021, the EU Cancer Mission should have clear elements within its programme 
that support the WHO global strategy for the elimination of cervical cancer as 
a public health problem and the European Cancer Organisation 2019 European 
Cancer Summit resolution on the elimination of cancers caused by HPV. This 
should include supporting research priorities such as new vaccine and screening 
technologies as well as care and treatment modalities. Research is also needed 
into the vaccination of women found to be HPV-positive at cervical cancer 
screening as a way of interrupting the transmission of the virus into the community.
• EU Cancer Mission goals, such as on HPV, should be complemented by an EU 
Cancer Masterplan that supports achievement in respect to non-research-related 
matters. This might include facilitating greater use of EU structural funds to achieve 
EU- and WHO Europe-wide HPV vaccination, cervical cancer screening, and 
treatment goals for HPV-related cancers. 
• As part of the coordination role that the EU should play in assisting member states 
to combat cancer by 2025, a public monitoring and reporting exercise should be 
established in respect of EU Member State cancer plans, similar to ‘the State of 
Health in the EU’ exercise. This should include the monitoring of actions towards 
goals on HPV-related cancer elimination. Such a mechanism could be developed 
within the context of the European Cancer Dashboard suggested within the 
European Parliament Research Service Report ‘Strengthening Europe in the Fight 
Against Cancer’.97
Cross-Cutting Recommendations
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